Sinovac Participates in Three Investor Conferences in September 2010
BEIJING, Sept. 7 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that Mr. Weidong YIN, Chairman, President & CEO, Mr. Jacob Chik Keung HO, Acting CFO and Ms. Xiaohong WU, Senior Financial Manager, are scheduled to participate in three upcoming investor conferences to be held in September 2010.
-- Morgan Stanley Global Healthcare Unplugged Conference, New York, NY, September 13-14: Sinovac's presentation is scheduled for Tuesday, September 14 at 2:10 pm ET. -- Morgan Stanley China Global Healthcare Day, Boston, MA, September 15: Sinovac is participating in one-on-meetings with investors that day. -- UBS Global Life Sciences Conference, New York, NY, September 20-23: Sinovac's presentation is scheduled for Monday, September 20 at 10:00 am ET.
A live webcast of the presentations at the Morgan Stanley Global Healthcare Unplugged Conference and at the UBS Global Life Sciences Conference will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com .
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact: Chris Lee Sinovac Biotech Ltd. Tel: +86-10-8279-9659 Fax: +86-10-6296-6910 Email: [email protected] Investors: Stephanie Carrington/Amy Glynn The Ruth Group Tel: +1-646-536-7017/7023 Email: [email protected] [email protected] Media Jason Rando The Ruth Group Tel: +1-646-536-7025 Email: [email protected]
SOURCE Sinovac Biotech Ltd.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article